DBC Research USA

Pembroke Pines, Florida 33029

2 studies enrolling now · 16 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, COVID-19, COVID-19 SARS-CoV-2 Infection, Cardiovascular Disease, Clostridoides Difficile Associated Disease, Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease, Eosinophilic Esophagitis, Hyperlipidemia, Influenza, Influenza, Human, Lower Respiratory Tract Illness, Primary Prevention of Atherosclerotic Cardiovascular Disease

Studies at this site

• A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease — Recruiting now
• Pelacarsen Roll-over Extension Program — Recruiting now
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD — Completed
• To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults — Running, not enrolling
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age — Running, not enrolling
• Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. — Running, not enrolling
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. — Completed
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza — Completed
• A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older — Completed
• A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized — Completed
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza — Completed
• Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early